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Abstract – Infectious bursal disease (IBD), also known as the Gumboro disease, has been a great 
concern for poultry industry worldwide. The first outbreak of IBD due to very virulent (vv) IBD virus 
(IBDV) infection in Malaysia was reported in 1991. The major economic impact of the disease is high 
mortality and poor performance. The virus causes immunosuppression where if the infected chicken 
recovered from the acute disease, they become more susceptible to infections of other pathogens and 
fail to respond to vaccines. Therefore, prevention is important and vaccination has become the 
principal control measure of IBDV infection in chickens. The conventional attenuated live and killed 
vaccines are the most commonly used vaccines. With the advancement of knowledge and technology, 
new generation of genetically-engineered vaccines like viral vector and immune complex vaccines 
have been commercialised. Moreover, hatchery vaccination is becoming a common practise, in 
addition to farm vaccination. Currently, the disease is considerably under controlled with the 
introduction of vaccination. However, occasional field outbreaks are still commonly reported. The 
demand for vaccines that could suit the field situation continues to exist. The endemicity of disease, 
presence of challenge in the farm and maternally derived antibody in chicks are affecting the choice 
vaccine as well as the vaccine development and vaccination strategies. In this review, advances made 
in various vaccines that have been commercialised or under development, and challenges that they 
face, are outlined. Furthermore, how the emergence of vvIBDV affect the progress of vaccine 
development and influence its vaccination strategy are discussed. 
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Introduction 
Infectious bursal disease (IBD)  also known as the Gumboro disease was first reported from broiler 
flocks in the area of Gumboro, Delaware in 1957 (Eterradossi & Saif, 2008). The causative agent of 
the disease was identified as the IBD virus (IBDV), which is the prototype member of the genus 
Avibirnavirus. Together with infectious pancreatic necrosis virus from genus Aquabirnavirus, 
Drosophila X virus from genus Entomobirnavirus, blotched snakehead virus and rotifer birnavirus, 
they form the family Birnaviridae (Delmas et al., 2005). The members of the family possess two 
genome segments of double stranded RNA, within a single-shelled, non-enveloped capsid of 
icosahedral symmetry and a diameter of about 60 nm (Nick, Cursiefen, & Becht, 1976; Müller, 
Scholtissek, & Becht, 1979; Azad, Barrett, & Fahey, 1985). The IBDV genome segments are named 
A and B. Segment A encodes for two partially overlapping open reading frames (ORFs), where the 
large ORF produces a precursor polyprotein that is proteolytically cleaved to yield precursor VP2 
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(pVP2), VP4 and VP3 (Hudson, McKern, Power, & Azad 1986; Sánchez & Rodriguez, 1999). The 
pVP2 undergoes a series of cleavage to become mature VP2 (Müller & Becht, 1982; Irigoyen et al., 
2009; Irigoyen, Castón, & Rodríguez, 2012). The smaller ORF preceding and partially overlapping 
the large ORF encodes for the fifth identified IBDV protein VP5 (Mundt, Beyer, & Müller, 1995). 
The genome segment B encodes for polypeptide VP1 (Morgan, Macreadie, Harley, Hudson, & Azad, 
1988). Two serotypes of IBDV are identified namely the serotypes 1 and 2. The serotype 1 is 
pathogenic in chickens and consists of three viral strains namely the classical (ca), very virulent (vv) 
and variant (va) IBDV. The serotype 2 is non-pathogenic in chickens.   
 
The clinical acute outbreaks of caIBD in susceptible flocks are generally shown by sudden onset of 
high mortality. The birds often appear prostrated and unwilling to move with ruffled feathers. They 
frequently pick at their own vents and have soiled vent feathers from the watery or whitish diarrhoea 
(Eterradossi & Saif, 2008). Under commercial set up, the disease can cause up to 20% mortality in 
susceptible hybrid Leghorn replacement pullets (Lasher & Shane, 1994). Experimental infections in 
specific-pathogen-free (SPF) chickens resulted in a range a mortality rates, from 0 to 30% by the US 
standard challenge IBDV strain STC (Stoute et al., 2013). The IBDV such as the British strain F52/70 
could induce up to 36% mortality while that of German strain Cu-1WT could cause up to 54% 
mortality in SPF chickens (van den Berg et al., 2004). 
 
The mortality rate from the disease in broiler chickens seldom exceeded 2% (van den Berg, 2000). 
Furthermore, the infection may be less severe and could frequently go undetected due to the presence 
of maternally derived antibody (MDA) in endemic farms. However, increased carcasses 
condemnation rate in processing plants due to haemorrhages in the thigh and pectoral muscles from 
the clinical disease resulted in economic losses (Kibenge, Dhillon, & Russell, 1988). In fact, the 
economic significance was mainly due to immunosuppressive effect of the disease (Sharma, Dohms, 
& Metz, 2000). In certain circumstances, such as subclinical infection in chickens less than 3 weeks of 
age, it may result in immunosuppression (Lasher & Shane, 1994). The recovered chickens become 
more susceptible to infections of other pathogens such as viruses and bacteria, and fail to respond to 
vaccines. Depending on the nature of the disease, the immunosuppressed chickens may suffer from 
the secondary infection at later age at around 4- to 5-week-old in broiler or later in layer flocks. In 
view of this, a live vaccine using a mild or attenuated isolate of the virus was produced in SPF 
embryonated chicken eggs (Snedeker, Wills, & Moulthrop, 1967). Since then, the disease was 
satisfactorily controlled by vaccination. 
 
Emergence of the Variant and Very Virulent IBDV Strains 
In the 1980’s, vaccination failures and outbreak of the disease were reported from different parts of 
the world. The caIBDVs were experiencing a pathotypic shift and breaking through MDA in 
vaccinated chickens (Snyder, 1990). In the U.S., the control was compromised by the appearance of 
new IBDV variants (Jackwood & Saif, 1987). Although the new variants were genetically and 
phylogenetically related to the serotype 1 caIBDV, they demonstrated a distinct antigenicity pattern 
(Heine, Haritou, Failla, Fahey, & Azad, 1991). The variant strains were reported to induce little if any 
clinical signs and mortality, but could cause rapid bursal atrophy (Sharma, Dohms, & Metz, 1989). 
Although the variant strains are mainly confined to the U.S., the appearance of vaIBDV strains has 
later been reported in Australia as well (Sapats & Ignjatovic, 2000).  These viruses were not only 
antigenically different from the variant strains in the U.S., but also demonstrated distinct genetic and 
phylogenetic relationships to that of the US variants (Sapats & Ignjatovic, 2000). 
 
At the same time, in the 1980’s the IBDVs were undergoing a pathotypic shift in Europe in at a 
practically opposite direction to that of the variant strains in the U.S. and identified as vvIBDV (van 
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den Berg, Gonze, & Meulemans, 1991). The new virus isolates demonstrated an increased virulence 
that could experimentally reproduce up to 100% mortality in SPF chickens. The disease spread 
worldwide; in the early 1990’s, the appearance of vvIBDV was reported in Japan (Nunoya, Otaki, 
Tajima, Hiraga, & Saito, 1992; Lin et. al., 1993). Since then, vvIBDV has quickly spread all over 
Asia (van den Berg, 2000), including Malaysia in 1991 (Hair-Bejo, 1992). The virus has also been 
isolated in other major parts of the world like Central Europe, Russia, the Middle East and South 
America (van den Berg, 2000), and in December 2008, the first case of vvIBDV outbreak was 
reported from pullet flocks in California, U.S. (Stoute et al., 2009). 
 
The vvIBDV infection produces clinical disease signs similar to that of the caIBDV, except with an 
aggravated clinical signs in susceptible flocks (van den Berg, 2000). Under natural set up in endemic 
infection, the virus could induce up to 30% mortality in broilers and 60% in layers (Eterradossi et al., 
1999). While under experimental conditions, the vvIBDV can induce up to 100% mortality in SPF 
chickens (van den Berg, 2000). The disease pattern of the flocks shows mortality peaks with a sharp 
death curve that is followed by rapid recovery. The clinical disease is characterised by higher 
mortality rates and extended age of susceptibility. 
 
With the emergence of vaIBDV and vvIBDV strains, rapid identification and characterisation of new 
IBDV isolates become important and three criteria have been used to assess and characterise the 
IBDV strains. In addition to the pathogenicity characteristics in SPF chickens, IBDV strains are also 
being grouped by their antigenicity and genetic relatedness profiles (van den Berg et. al., 2004). 
Although cross neutralization tests and sequence analyses to characterise IBDV are established, 
almost all of them are based on the VP2 region of IBDV (Lana, Beisel, & Silva,; van den Berg et. al., 
1996; Sapats & Ignjatovic, 2000; Remorini et. al., 2006). Furthermore, recent progress in the IBDV 
research have revealed the occurrence of natural IBDV reassortant strains (Wei et al., 2006; Le Nouën 
et al., 2006; Jackwood et al., 2011) or mosaic virus from homologous recombination within segments 
(Hon et al., 2008; He et al., 2009; Jackwood, 2012a), which demonstrated the insufficiencies of using 
VP2 alone for grouping of IBDV isolates. Experimental studies showed that the viral segment B does 
influence the virulence and disease outcome (Le Nouën et al., 2012; Escaffre et al., 2013; Yu et al., 
2013). Certainly, this has called for characterisation of IBDV to be based on both genome segments A 
and B in order to achieve better control of the disease (Jackwood et al., 2011; Escaffre et al., 2013; 
Liew, Omar, Ideris, & Hair-Bejo, 2013). 
 
Vaccination against IBD 
As the IBD virus is stable in nature and resistant to many physical and chemical disinfectants, IBDV 
infections continue to occur and spread widely despite a properly done cleaning and disinfection 
procedures (van den Berg, 2000). Therefore, vaccination becomes the principal control measure of 
IBDV infection in chickens (Eterradossi & Saif, 2008). In the early days, protection was sufficiently 
achieved by active immunisation of breeding hens with combination use of live and inactivated 
vaccines (Lasher & Shane, 1994; Nagarajan & Kibenge, 1997). In replacement pullets that have been 
primed with live vaccine at 4 to 8 weeks of age, inactivated oil-emulsion vaccine is being 
administered before lay to boost antibody production that are transferable to chicks. In layer strain 
parent stocks, the booster dose is administered between 16 and 18 weeks of age while in broiler 
breeders it is performed at 20 weeks of age (Lasher & Shane, 1994). Later, a mid-cycle booster is 
done at around 40 to 42 weeks of age to induce a high MDA and long-lasting serum titer.  
 
Compared to live attenuated embryo-propagated virus, booster vaccination with inactivated IBDV in 
oil-emulsion demonstrated a far more superior immunogenicity in hens, and a longer persistence of 
MDA in chicks (Lasher & Shane, 1994). The MDA was able to provide passive immunity to the 
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chicks (Wyeth & Cullen, 1976) for 4 to 5 weeks of life (Lucio & Hitchner, 1979; Naqi, Marquez, & 
Sahin, 1983). It was shown that the higher the MDA in chicks, the longer the protection could last 
(Al-Natour et al., 2004). The MDA protect them from subclinical IBD and therefore prevent the 
detrimental immunosuppression effects associated with early age infection (Lucio & Hitchner, 1980). 
However, the level of protection afforded by MDA depends not only on strain present in the 
inactivated vaccine, but also the degree of virulence of the IBDV challenge strain (Maas et al., 2001). 
They require a higher level of MDA against more virulent challenge virus in order to achieve 
complete protection against clinical disease (Maas et al., 2001). 
 
The emergence of vvIBDV, however, has brought the conventional vaccination programme into 
question (van den Berg, 2000). The vvIBDVs were able to break through the MDA in chicks (van den 
Berg & Meulemans, 1991; Maas et al., 2001; Zorman-Rojs, Barlič-Maganja, Mitevski, Lübke, & 
Mundt, 2003; Jackwood et al., 2009). It was shown that maximum mortalities of 60% in layers and 20% 
in broilers were recorded from chicks with MDA when challenged at the age of 38 days old (van den 
Berg & Meulemans, 1991). Although the chicks were protected against mortality at the age earlier 
than 38 days old, they nevertheless suffered extensive damage in the bursa of Fabricius. Similarly in 
the U.S., progenys from hens vaccinated with the serotype 1 caIBDV and vaIBDV were shown to 
succumb to clinical disease and infection when challenged with high dose of vvIBDV (Jackwood et 
al., 2009). The chicks demonstrated bursal lesions and positive for IBDV viral genome upon RT-PCR 
although no mortality was detected. In an experiment mimicking the field situation in the U.S. 
involving competition from the endemic vaIBDV, it was shown that co-infection of both vvIBDV and 
vaIBDV in SPF chickens at the same time resulted in clinical disease typical of vvIBDV infection 
(Jackwood, 2011). However, the mortality rates were comparatively lower at between 30% and 40% 
than the positive control birds where they all died following infection by vvIBDV alone. And when 
the variant virus was inoculated at 2 days earlier, the occurrence of clinical signs, macroscopic and 
microscopic bursal lesions, as well as the viral load were reduced (Jackwood, 2011). Interestingly, 
infection at 10 days apart excluded the vvIBDV from establishing an infection as the variant viruses 
have destroyed most of the susceptible B lymphocytes (Jackwood, 2011). 
 
Conventional IBD Vaccines 
In view of the changing situation in the field, immunisation with live vaccines become necessary to 
protect the chicks from vvIBDV infection and disease during the growing period (van den Berg & 
Meulemans, 1991). Although inactivated IBDV has been tested for oral immunisation in 3-week-old 
SPF chicks and was shown to be protective (Hoshi, Nakamura, Nunoya, & Ueda, 1995), the use of 
killed vaccines is mainly practised in breeder flocks to boost and prolong humoral immunity (van den 
Berg, 2000). 
 
There are many choices of live vaccines and could be subjectively classified from mild, mild to 
intermediate, intermediate, intermediate plus or ‘hot’ (Eterradossi & Saif, 2008). Mild vaccine strains 
such as PBG98 and Lukert, as well as cell-culture adapted strain break through virus-neutralising (VN) 
titer of less than 1:100 and could be used in chicks with MDA titer less than 1:1000 (Skeeles, Lukert, 
Fletcher, & Leonard, 1979; Eterradossi & Saif, 2008). As the MDA in chicks decay over time with a 
half-life of about 4 days, high level of MDA during the early life may neutralise the mild vaccine 
viruses (Winterfield & Thacker, 1978; van den Berg et al., 1991; Tsukamoto et al., 1995) and they are 
therefore not advisable to be used in the first vaccination of the progeny (van den Berg, 2000).  
 
Intermediate vaccines like D78 and SAL and ‘hot’ vaccine strains on the other hand could break 
through a VN antibody titers of 1:250 and 1:500, respectively (Eterradossi & Saif, 2008). They could 
neutralise the MDA and induce the development of active immunity in chickens, thus provide 
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protection to the chicks upon field virus challenge (Winterfield & Thacker, 1978; Rautenschlein et al., 
2005). It was shown that the ‘hot’ vaccine stimulated antibody production as early as 14 days post-
vaccination in the presence of maternal VN antibodies while the intermediate vaccines took longer to 
induce the production of circulating IBD antibodies at 21 days post-vaccination (Rautenschlein, 
Kraemer, Vanmarcke, & Montiel, 2005). Nevertheless, intermediate vaccine was ineffective and 
failed to induce IBD antibody when administered via oral or eye-drops to chicks of one-day-old with 
high MDA (Hair-Bejo, M., Ng, & Ng, 2004).  
 
Although the use of intermediate and intermediate plus vaccines do not induce mortality, they could 
produce severe bursal lesions and possibly resulted in immunosuppression in vaccinated chickens 
(Winterfield & Thacker, 1978; Rautenschlein, Yeh, & Sharma, 2003; Hair-Bejo et al., 2004; 
Rautenschlein et al., 2005; Eterradossi & Saif, 2008). In addition, Bursine 2 IBDV intermediate strain 
has been shown to cause lesions in non-bursal tissues like the spleen (Rautenschlein et al., 2003). It 
was shown that viral antigens were detected in spleens from up to two thirds of the chickens 
vaccinated with intermediate vaccine strains, whereas the intermediate plus vaccine practically 
induced a severe bursal lesion resembling that of bursectomy (Rautenschlein et al., 2005). It was 
speculated that the ‘hot’ vaccine viruses cause a severe destruction to the target lymphoid B cells, and 
thus able to reduce the impact of disease upon challenge with wild type virus. The use of ‘hot’ 
vaccines, although providing protection, is not safe as they carry higher inherent risk of reversion to 
virulence and may result in immunosuppression in chickens (van den Berg, 2000). Therefore, in an 
effort to develop appropriate vaccination programme for the farm, interference of MDA have become 
a critical factor in choosing the right vaccines (van den Berg, 2000). Flock profiling to determine the 
MDA levels in chicks and thereby predict the appropriate age for first vaccination is important 
(Eterradossi & Saif, 2008). 
 
New Generation or Genetically-Engineered IBD Vaccines 
In addition to the conventional live and inactivated vaccines, genetically engineered IBD vaccines 
have also been developed as a result of improved understanding on the molecular structure and 
immunology of IBDV (Nagarajan & Kibenge, 1997). Generally, these could be divided into two main 
categories, reflective of their replicative nature upon delivery into the chicken. 
 
Non-replicative IBD vaccines 
Immunisation by DNA or subunit vaccines involve the use of non-replicating IBDV for induction of 
immune response in birds. DNA vaccination is based on direct inoculation of plasmid DNA encoding 
a target immunogen gene into subjects of study (Oshop, Elankumaran, & Heckert, 2002). Under the 
influence of a mammalian promoter, the target genes were expressed to produce proteins in vivo that 
are able to induce immune responses in the injected host. Repeated injections of DNA vaccines 
carrying the IBDV genes, either the polyprotein genes or gene of VP2 alone were shown to protect the 
chickens from challenge virus (Chang, Lin, & Wu, 2002; Chang, Lin, & Wu, 2003; Kim, Sung, Han, 
Jackwood, & Kwon, 2004; Hsieh, Wu, & Lin, 2010; Chen et al., 2011). However, the presence of 
MDA could affect the efficacy of DNA vaccines and a high dose of DNA vaccines was required to 
overcome the interference of MDA and induce immune response in chickens (Hsieh et al., 2010). In 
contrast to conventional live attenuated vaccines, DNA vaccines induce a low and nearly undetectable 
anti-IBDV antibody titers in ELISA (Chang et al., 2002; Chang et al., 2003). Even after virus 
challenge, it was reported that ELISA titres were low and some remained below the cut-off titer of 
396 as given by the ELISA kit (Chang et al., 2002; Chang et al., 2003) although a separate study 
demonstrated otherwise (Kim et al., 2004). A closer look into these two studies revealed the 
difference in the virulence of the challenge viruses used that might influence the post-challenge 
ELISA readings. In one of the trial from earlier study, the challenge virus used was a caIBDV STC 
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that induce from 0 to 20% mortality in the unvaccinated chickens (Chang et al., 2002).  In  another 
study, the SH/92 vvIBDV was used and demonstrated to cause 90% mortality in unvaccinated and 
challenged control chickens (Kim et al., 2004). The two studies nevertheless observed that almost all 
chickens vaccinated with DNA vaccines demonstrated antibody level not significantly different from 
the unvaccinated and challenged control. 
 
In fact, the working mechanisms of DNA vaccines have not been fully elucidated and the work is still 
in its infancy (Oshop, Elankumaran, & Heckert, 2002). Nevertheless, many efforts have been made to 
improve the efficacy of DNA vaccines. For example, simultaneous administration of plasmid DNA 
carrying chicken cytokines like IL-2 (Hulse & Romero, 2004; Li et al., 2004), IL-6 (Sun, Yan, Jiang, 
& Lu, 2005), or IFN-γ (Hsieh et al., 2006) were attempted to enhance the immune responses and 
thereby increase the level of protection. Furthermore, studies taking on the advantage of adjuvants 
such as CpG oligodeoxynucleotides (Wang et al., 2003), cationic liposome (Li, Huang, Liang, Lu, Li, 
Yu, & Deng, 2003), or defensins (Zhang et al., 2010) for DNA vaccines have also been reported. As 
DNA vaccination is still in trial  stage, in addition to adjuvant, other factors such as  the sequence of 
the target genes, choice of eukaryotic expression vector, route of administration, immunisation dosage 
and frequencies for  proper optimization (Li et al., 2003). Moreover, it was shown that a booster 
vaccination with inactivated IBD vaccine after priming with DNA vaccine provided better and higher 
protection to the chickens compared to injection with DNA vaccines alone, demonstrating the 
importance in designing appropriate vaccination strategy when using different types of vaccines 
(Hsieh et al., 2007). 
 
Subunit vaccination, on the other hand, involves immunisation with IBDV proteins expressed from in 
vitro systems like the baculovirus (Vakharia et al., 1993; Pitcovski et al., 1996; Dybing & Jackwood, 
1997; Wang et al., 2000; Martinez-Torrecuadrada et al., 2003) or yeast (Fahey et al., 1991; Pitcovski 
et al., 2003; Villegas, Hamoud, Purvis, & Perozo, 2008). The generated recombinant protein, mainly 
the VP2 protein emulsified in oil adjuvants, has been shown to provide protection against the disease 
when given to the chickens (Vakharia et al., 1993; Pitcovski et al., 1996; Dybing & Jackwood, 1998; 
Pitcovski et al., 2003; Villegas, Hamoud, Purvis, & Perozo, 2008) and progenies from the vaccinated 
hens were also shown to be passively protected (Fahey et al., 1991; Vakharia et al., 1994; Yehuda et 
al., 2000). Such findings have highlighted the potential of recombinant vaccines in replacing the 
conventional inactivated vaccines and functioning as the booster vaccine in vaccination programme of 
the breeding hens.  
 
Furthermore, the virus-like particles (VLPs) of IBDV have been produced through the baculovirus 
expression system (Kibenge, Qian, Nagy, Cleghorn, & Wadowska, 1999; Hu, Bentley, Edwards, & 
Vakharia, 1999; Jackwood, 2012b), and when used in immunisation trials, it was shown that the crude 
VLPs elicited immune responses in vaccinated chickens (Jackwood, 2012b). Compared to the 
chickens in the unvaccinated and challenged control group where all developed lesions in the bursa of 
Fabricius, up to 90% to 100% of the chickens vaccinated with crude VLPs were protected from bursal 
lesions upon challenge (Jackwood, 2012b). Nevertheless, the efficacy of the recombinant IBDV 
subunit vaccine was conformational dependent  as chickens vaccinated with particulates containing 
VP2 capsids were shown to induce stronger neutralising antibodies than those vaccinated with pVP2 
(VPX) tubules or polyprotein-derived mixture of VLPs and capped tubules (Martinez-Torrecuadrada 
et al., 2003). 
     
Replication-competent IBD vaccines 
In addition, replication-competent viral vectors have been utilized to express and deliver immunogens 
of interest to chickens. In contrast to DNA and subunit vaccines, vaccination by live recombinant 
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virus vectors employed the use of live and replicating virus to produce IBDV antigen upon in vivo 
infection (Tsukamoto et al., 2002). They have been shown to elicit both humoral and cell-mediated 
immune response in the chickens. As they could persistently infect the chickens, the potential of 
having a long-term protective immunity is high (Tsukamoto et al., 2002). Besides, the recombinant 
viral vectors are less sensitive to MDA and could therefore evade the neutralisation by the maternal 
anti-IBDV antibody (van den Berg, 2000). 
 
Several viruses have been experimented to express the VP2 protein of IBDV.  This includes fowlpox 
virus (Bayliss et al., 1991; Heine & Boyle, 1993), turkey herpesvirus (Darteil et al., 1995; Tsukamoto 
et al., 2002; Perozo, Villegas, Fernandez, Cruz, & Pritchard, 2009), fowl adenovirus (Sheppard et al., 
1998), Marek's disease virus (Tsukamoto et al., 1999), Newcastle disease virus (Huang et al., 2004), 
and avian adeno-associated virus (Perozo, Villegas, Estévez, Alvarado, & Purvis, 2007) among others. 
The VP2 protein expressed in vivo from these various studies have been shown to confer from partial 
to full protection to vaccinated chickens from mortality, although they do not prevent the damage to 
the bursa (Bayliss et al., 1991; Heine & Boyle, 1993; Sheppard et al., 1998; Tsukamoto et al., 1999; 
Tsukamoto et al., 2002; Huang, Elankumaran, Yunus, & Samal, 2004; Perozo et al., 2008; Perozo et 
al., 2009; Zhou et al., 2010). Further, the commercially available recombinant herpesvirus of turkey 
vaccine expressing the IBDV VP2 antigen (Vaxxitek®; Merial) has been shown to induce immunity 
and confer protection to the chicks in the face of MDA (Bublot et al., 2007; Lemiere et al., 2011b). 
The vaccine has also been shown to be suitable for day-old chicks and compatible with vaccines like 
Marek’s disease (Lemiere et al., 2011a) and Newcastle disease for hatchery vaccination (Lemiere et 
al., 2011b). 
 
In addition, through the chimeric virus particles (CVPs) that employ epitope presentation strategy, 
insect baculovirus displaying IBDV VP2 gene (Xu et al., 2011) or plant Bamboo mosaic virus 
presenting the VP2 P domain loop PBC of a vvIBDV (Chen et al., 2012) has  been produced. These 
studies showed that the recombinant viruses were able to induce protective immunity upon IBDV 
challenge, highlighting the feasibility of using CVPs for propagation of recombinant vaccine virus in 
non-animal system. 
 
The reverse genetic system is another approach to produce live and replicating IBDV (Mundt & 
Vakharia, 1996; Boot, ter Huurne, Peeters, & Gielkens, 1999). Infectious virus could be rescued from 
the cell cultures transfected by synthetic RNA (Mundt & Vakharia, 1996) or cDNA (Boot et al., 1999) 
sequences of IBDV. The system allows deliberate manipulation of the IBDV genes and thus produce 
attenuated strains with desired vaccine characteristics (van Loon, de Haas, Zeyda, & Mundt, 2002; 
Qin et al., 2010; Gao et al., 2011). Targeted mutagenesis at specific amino acids of VP2 have allowed 
direct adaptation of the vvIBDV to chicken embryo cell culture without going through extensive 
passages in cell culture, chorioallantoic membrane, or yolk sac of embryonated eggs (Lim, Cao, Yu, 
& Mo, 1999; van Loon et al., 2002). The cell culture adapted vvIBDV was shown to be significantly 
attenuated in chickens and failed to induce mortality upon infection (van Loon et al., 2002). In 
addition, IBDV with deleted VP5 gene (Qin et al., 2010) or containing cell culture adapted VP2 gene 
of the vvIBDV (Gao et al., 2011) were shown to confer protection to chickens upon challenge by the 
vvIBDV. Even though the use of reverse genetic system permits generation of new vaccines with 
desired characteristics, they have the risk of reversion (Raue et al., 2004). It was shown that infection 
of the cell culture adapted IBDV in commercial chickens had seen the virus reverted to wild-type 
phenotype on 3 days post-inoculation. Besides, the use of rescued virus as vaccines will still need to 
face the interference of MDA (van den Berg, 2000). 
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Although the high titer of MDA has been linked to neutralisation of IBDV vaccines when given to 
day-old commercial chicks, it was speculated that the vaccine virus actually formed complexes with 
maternal antibodies (Rautenschlein et al., 2005). This is highly possible because IBD immune 
complex formulated by mixing live IBDV with anti-IBDV antibodies has been shown to be 
efficacious when used as vaccine (Whitfill et al., 1995). Day-old SPF chicks inoculated with the 
immune complexes were shown to have delayed appearance of lesions in the bursa until after 6 to 8 
days of age and demonstrated active antibody production at 22 days old, which coincided with the 
induction of bursa lesions (Whitfill et al., 1995). Likewise, the use of immune complex for day-old 
IBD vaccination in commercial chicks with MDA has seen the development of active immunity and 
protection from challenge in these chicks (Haddad et al., 1997). Interestingly, such phenomenon has 
been observed with the use of the less attenuated ‘hot’ vaccines, where they induced the production of 
antibody in the presence of MDA that was correlated with the appearance of lesions and detection of 
IBDV antigen in the bursa of Fabricius (Rautenschlein et al., 2005). Indeed, it was proposed that the 
immune complex vaccine was initially trapped within the follicular dendritic cells in both the spleen 
and bursa (Jeurissen et al., 1998). The virus were then released from the antibody possibly through 
dissociation, degradation, or a mechanism yet to be known, and caused infection to chickens. 
Nevertheless, how the type of MDA present within the chicks and the degree of virulence of challenge 
virus in the field can influence the protective efficacy of the immune complex IBD vaccine would 
require further studies. 
 
In ovo Vaccination 
In contrast to at-hatch or post-hatch vaccination using either conventional or newer generation 
molecular-based IBD vaccines that have been described earlier, in ovo vaccination generally deliver 
vaccines to the chicken embryo at around 18 days of incubation by automated injection through the 
eggshells (Johnston et al., 1997). This reduces the handling cost of post-hatch or on-farm vaccination. 
The approach of using immune complex IBD vaccine has been tested in in ovo vaccination and shown 
to confer protection to chicks upon challenge on day 21 or 28 post-hatch (Johnston et al., 1997). The 
18-day old chicken embryo inoculated in ovo did not develop bursal lesions until 5 days after hatching 
and showed increased antibody production between 21 to 28 days of age concomitant with diminished 
MDA levels (Johnston et al., 1997). Depending on the level of MDA in commercial chicks, the 
immune complex vaccine when given in ovo could protect up to 83% of the broilers from bursal 
lesions upon challenge (Corley, Giambrone, & Dormitorio, 2002), although the percentage is lower in 
SPF chicks (Corley, Giambrone, & Dormitorio, 2001).  
 
In addition to immune complex vaccines, live attenuated IBD vaccines (Sharma, 1986; Coletti et al., 
2001; Giambrone, Dormitorio, & Brown, 2001), DNA vaccine carrying IBDV VP2 gene (Haygreen, 
Kaiser, Burgess, & Davison, 2006), or recombinant Newcastle disease virus expressing VP2 gene of a 
vvIBDV (Ge et al., 2014) have also been tested in ovo. Compared to post-hatch vaccination, in ovo 
injection of a live intermediate vaccine allowed faster recovery from bursa lesions although both 
methods exhibited similar protection against challenge (Rautenschlein & Haase, 2005). Experiments 
showed that the in ovo vaccination with live intermediate vaccines provided complete protection to 
the SPF birds against challenge (Coletti et al., 2001; Rautenschlein & Haase, 2005) while the 
protection was partial in the commercial broilers (Coletti et al., 2001; Giambrone et al., 2001). 
Depending on the virulence and dosage of the vaccine strains, vaccination in ovo may cause increased 
of post-hatch mortality (Giambrone et al., 2001) and immunosuppression (Corley & Giambrone, 
2002). Although in ovo delivery of vaccines is an attractive alternative to post-hatch vaccination, 
various factors including the dosage, virulence, and efficacy, among others must be properly 
optimized before pursuing large scale vaccinations. 
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Plant-Produced IBD Vaccines 
The plant-based expression system is a growing alternative platform for production and development 
of animal vaccines (Floss, Falkenburg, & Conrad, 2007; Liew & Hair-Bejo, 2015). Being one of the 
pathogenic agents of importance in poultry, plant-based expression system using the stable (Wu et al., 
2004; Wu et al., 2007; Liew et al., 2015), transient (Gómez et al., 2013), or chimeric viral particles 
(Chen et al., 2012) approach has been used to produce IBD vaccine containing VP2 capsid protein. 
Transgenic rice expressing the VP2 protein was shown to protect the chickens from challenge 
following oral immunisation (Wu et al., 2007). Compared to chickens that received live attenuated 
vaccine, chickens fed orally with transgenic rice achieved better lesion score when evaluated based on 
lesion scoring of the bursa after challenge. Moreover, immunofluorescence assay revealed that the 
amount of antigen present in the bursal tissue was also lesser in the orally immunised chickens (Wu et 
al., 2007). 
 
Recently, the VP2 protein of IBDV has been transiently expressed in Nicotiana benthamiana leaves 
and extracted for subunit vaccination in chicken (Gómez et al., 2013). The recombinant VP2 protein 
emulsified in oil adjuvant, injected intramuscularly to chicks at 18 days of age and followed by 
booster doses after 22 and 35 days, were shown to induce the production of anti-IBDV antibody with 
neutralising ability in these chicks. Further, replication-competent viral vector using plant virus has 
been studied for its feasibility for production of IBDV proteins in plant-based expression system. It 
was shown that the CVPs carrying an immunogenic domain of VP2 were viable and allowed for 
propagation in plants (Chen et al., 2012). Moreover, the CVPs emulsified in oil adjuvant were able to 
induce IBDV-specific antibodies in 3-week-old SPF chickens and protected them against challenge 
from a vvIBDV at 28 days post-vaccination (Chen et al., 2012). These studies have concluded that 
plants represent a promising expression system for the mass production of immunogenic proteins that 
can be conveniently used as vaccines for chickens. 
 
Conclusion and Perspectives 
Thus far, four types of IBD vaccines are commercially available in Malaysia for prevention of IBD, 
which include the conventional attenuated live or killed vaccines, and new generation viral vector 
based vaccines using herpesvirus of turkey and IBD immune complex vaccine. Many IBD vaccines 
produced in the newer generation production systems have yet to make it to commercialisation, 
mainly due to issues like safety and protective efficacy. As animal experimental trials do not fully 
reflect the field condition, additional optimisation and testing in the field are required. On the other 
hand, how feasible a vaccine can be applied in the field depends not only on safety and efficacy, but 
also affordability and availability of the vaccine. The herpesvirus of turkey based viral vector and 
immune complex vaccines can be as much as 10 times more expensive than the conventional live or 
killed vaccines. Most poultry producers especially the small farm holders will therefore tend to shun 
away from the new generation IBD vaccines. The use of killed vaccines generally involve injections 
and could trigger tissue reactions, thus it is not suitable for use in broiler birds due to potential 
carcasses condemnation at slaughter house. Although the live attenuated vaccines represent the 
cheapest options of vaccine, interference of MDA is a critical factor in its implementation. The choice 
of live vaccines is also subjected to the endemicity of the disease; when the challenge is high, the use 
of intermediate and intermediate plus vaccines will be more practical and effective in preventing an 
outbreak. In addition, vaccination strategy, be it in ovo, at-hatch or on-farm vaccinations, determines 
the choice of vaccines used in the farm. Compared to farm vaccination, hatchery vaccination enables 
large scale operation with relatively lesser trained personnel and manpower. Most of the major poultry 
producers are more inclined to opt for hatchery vaccination as it could cut down the cost of production 
in the farm. It must be noted that no universal vaccination programme for IBD could be implemented 
in all farms due to factors influencing the maternal immunity, multifaceted nature of the disease, farm 
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conditions, as well as management decisions. Therefore, the feasibility in implementation of an IBD 
vaccine on the farm lies essentially on its vaccination programme in the farm, after taking into 
consideration on the safety, efficacy, affordability and availability of the vaccine. 
 
Infectious bursal disease has been an endemic viral disease of poultry worldwide and was first 
reported in Malaysia in 1991. Despite the introduction of vaccination, occasional outbreaks are still 
reported from the field. A growing body of evidence revealed that both genome segments A and B of 
IBDV contribute to the viral virulence and pathogenicity. It thus becomes crucial to carry out the 
examination on both genome segments A and B of IBDV for molecular diagnosis and genetic 
assessment. Moreover, this has also signified the importance to include IBDV genome segments A 
and B in the vaccine preparation as vaccination is the primary control of IBD in poultry. The current 
selection of IBD vaccines are insufficient under the ever changing disease situation in the field and 
the industry always thirst for a better vaccine to control the disease. Therefore, the needs for IBD 
vaccines that could be tailored and revised according to the field situation persist. Such incessant 
needs signify not only good prospects for continuous development towards ideal IBD vaccines, but 
also represent challenges to the researchers and scientists in designing effective vaccine that can be 
delivered to the field on a timely basis to quench the thirst. Likewise, appropriate and effective 
vaccination programmes must be established. The programme will require revision from time to time 
in pace with the changes in the field to protect the chickens from unintended outbreak or 
immunosuppression, and to allow for establishment of cost-effective vaccination schedules. With 
better and continuous advancement of knowledge on the molecular and immunological biology of 
IBDV, more safe and effective IBD vaccines that are affordable and readily available can be 
developed in a near future as a part of the initiative to curb the disease. 
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